Prevention of RSV disease in babies starts at HUS hospitals
RSV (respiratory syncytial virus) is the most common cause of respiratory infections leading to infant hospitalization. HUS offers an antibody developed against the RS virus called nirsevimab to infants and children who are at risk of severe RSV infection.
The aim of nirsevimab is to prevent the majority of severe illnesses and infant hospitalizations caused by RSV. Immunization with nirsevimab is voluntary and free of charge for families.
Nirsevimab is offered to all children born after August 1, 2024. HUS will offer nirsevimab to newborns in all its maternity hospitals from October 23, 2024. Children under the age of one year at risk for severe disease will be offered nirsevimab at HUS New Children's Hospital, Jorvi Hospital, and Hyvinkää Hospital from November 4, 2024, until the end of November.
The City of Helsinki and the wellbeing services counties of Uusimaa are responsible for administering nirsevimab according to their guidelines to healthy children born between August 1 – October 22, 2024
Nirsevimab is effective in preventing RSV infections
A long-acting antibody called nirsevimab is used to prevent RSV infections. It is administered as a single intramuscular injection. Nirsevimab is safe to administer even to newborns, and it provides efficient protection against RSV for the entire winter epidemic.
The product is very safe. It has been in use in several countries during the winter 2023–2024, where it prevented 80–90% of hospitalizations caused by RSV.
Keywords
Contacts
Director Jari Petäjä, p. 050 428 6630, jari.petaja@hus.fi
HUS Children and adolecents
Links
About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our more than 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
hus.fi/en
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Antalet fall av svår fästingburen hjärninflammation ökar – allt fler vårdas på sjukhus3.12.2025 10:03:20 EET | Pressmeddelande
Antalet fall av fästingburen hjärninflammation, det vill säga TBE är ökat betydligt från i fjol. Ökningen syns på HUS jourer, neurologiska avdelningarna samt också på intensivvårds- och intensivövervakningsavdelningarna. Fästingburen hjärninflammation har gått förbi herpesviruset som bidragande orsak till svåra hjärninflammationer.
Vaikea puutiaisaivotulehdus lisääntyy – yhä useampi joutui sairaalahoitoon3.12.2025 10:03:20 EET | Tiedote
Puutiaisaivotulehdusten (TBE) määrä on kasvanut selvästi viime vuodesta. Kasvu on näkynyt HUSissa päivystyksissä, neurologian osastoilla ja teho- ja tehovalvontaosastoilla. Puutiaisaivokuume on ohittanut herpesviruksen vaikeiden aivokuumeiden aiheuttajana.
Tick-borne encephalitis more common: number of hospitalized patients increased3.12.2025 10:03:20 EET | Press release
The number of tick-borne encephalitis cases (TBE) has clearly increased from last year. The increase has been evident at HUS emergency departments, on neurology wards, as well as on intensive and intermediate care units. TBE has surpassed herpesvirus as a leading cause of severe encephalitis.
HUS Euroopan yliopistosairaaloiden verkoston EUHA:n puheenjohtajaksi26.11.2025 10:42:34 EET | Tiedote
Puheenjohtajana HUS johtaa 11 eurooppalaisen yliopistosairaalan yhteistyötä seuraavat puoli vuotta. Puheenjohtajuuskaudella EUHA:n (European University Hospital Alliance) tulevaisuuden suunta määritellään strategian päivittämisen myötä.
Sammanslutningens styrelse godkände HUS-sammanslutningens budget för 202617.11.2025 12:49:00 EET | Pressmeddelande
Sammanslutningens styrelse godkände för egen del HUS-sammanslutningens budget för 2026 och ekonomiplanen för 2026–2028.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom